The company is particularly witnessing strong global gains in consumable revenues, banking on strong gains across its Catalyst, Premium Hematology and SediVue platforms. In 2024, consumable gains ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback